INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 319 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,861,610 | -41.5% | 90,500 | -24.6% | 0.04% | -48.8% |
| Q2 2023 | $4,893,600 | +9.4% | 120,000 | 0.0% | 0.09% | 0.0% |
| Q1 2023 | $4,472,400 | +36.3% | 120,000 | +27.6% | 0.09% | +65.4% |
| Q4 2022 | $3,281,405 | -70.8% | 94,050 | -53.2% | 0.05% | -66.7% |
| Q3 2022 | $11,252,000 | +65.7% | 201,106 | +53.3% | 0.16% | +66.0% |
| Q2 2022 | $6,790,000 | -69.9% | 131,180 | -57.8% | 0.09% | -65.3% |
| Q1 2022 | $22,577,000 | +386.0% | 310,700 | +690.9% | 0.27% | +421.2% |
| Q4 2021 | $4,645,000 | -70.5% | 39,286 | -66.6% | 0.05% | -71.1% |
| Q3 2021 | $15,763,000 | -89.7% | 117,500 | -87.5% | 0.18% | -91.0% |
| Q2 2021 | $152,699,000 | +360.7% | 943,100 | +128.4% | 1.99% | +179.9% |
| Q1 2021 | $33,143,000 | +509.1% | 413,001 | +313.0% | 0.71% | +474.2% |
| Q4 2020 | $5,441,000 | – | 100,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 752,024 | $100,884,000 | 18.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 420,859 | $56,458,000 | 4.40% |
| Discovery Value Fund | 922,411 | $123,741,000 | 3.63% |
| MPM BioImpact LLC | 162,620 | $21,815,000 | 3.38% |
| Ally Bridge Group (NY) LLC | 65,000 | $8,720,000 | 2.56% |
| ARK Investment Management | 6,743,556 | $904,648,000 | 2.17% |
| Integral Health Asset Management, LLC | 50,000 | $6,708,000 | 1.93% |
| Yorktown Management & Research Co Inc | 18,300 | $2,455,000 | 1.85% |
| Interchange Capital Partners, LLC | 8,191 | $1,098,000 | 1.84% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $14,950,000 | 1.76% |